1. Home
  2. ABUS vs CPF Comparison

ABUS vs CPF Comparison

Compare ABUS & CPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.40

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Logo Central Pacific Financial Corp New

CPF

Central Pacific Financial Corp New

HOLD

Current Price

$39.16

Market Cap

997.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
CPF
Founded
2005
1954
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
839.5M
997.1M
IPO Year
2008
2011

Fundamental Metrics

Financial Performance
Metric
ABUS
CPF
Price
$4.40
$39.16
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$5.00
$37.00
AVG Volume (30 Days)
2.7M
137.2K
Earning Date
05-14-2026
04-29-2026
Dividend Yield
N/A
3.39%
EPS Growth
55.26
45.18
EPS
0.87
0.78
Revenue
$14,083,000.00
$51,817,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$239.71
$4.62
P/E Ratio
$5.14
$49.59
Revenue Growth
128.21
33.81
52 Week Low
$3.25
$25.62
52 Week High
$5.38
$40.06

Technical Indicators

Market Signals
Indicator
ABUS
CPF
Relative Strength Index (RSI) 43.60 58.72
Support Level $4.16 $33.33
Resistance Level $4.69 $39.63
Average True Range (ATR) 0.24 0.91
MACD -0.06 -0.10
Stochastic Oscillator 11.95 57.80

Price Performance

Historical Comparison
ABUS
CPF

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About CPF Central Pacific Financial Corp New

Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.

Share on Social Networks: